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Abstract
Purpose
Invasive breast cancers are thought to arise from in situ lesions, but some ductal carcinoma
in situ (DCIS) are indolent with low likelihood of progressing to invasive carcinoma. Compari-
son of risk factor associations between DCIS and invasive disease may elucidate which fac-
tors influence early versus late stages of carcinogenesis. Therefore, we determined whether
there were differences in risk factor profiles for screen-detected DCIS and invasive breast
cancer among Luminal A lesions.
Methods
We conducted a case-control analysis using data from the Carolina Breast Cancer Study
(1993–2001). Analyses were restricted to Luminal A tumors and screen-detected tumors
among mammography-eligible women, to limit confounding by mode of detection (N = 108
DCIS; N = 203 invasive). Logistic regression was used to estimate odds ratios (OR) and
95% confidence intervals (CI) for associations between risk factors and lesion type.
Results
In stratified analyses, we observed qualitative differences in the direction of association for
ever smoking, obese BMI, high waist-to-hip-ratio (WHR), and�10 years of oral contracep-
tive use between DCIS and invasive disease. Breastfeeding was inversely associated with
invasive disease and was not associated with DCIS. Interaction tests for risk factor associa-
tions between Luminal A DCIS and invasive breast cancer were not statistically significant
(p>0.05).
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Conclusions
Among Luminal A tumors, established breast cancer risk factors may exert stronger effects
on progression of early lesions to invasive disease, with lesser effects on risk of DCIS.
Introduction
Breast carcinogenesis theories state that invasive breast cancers may arise from pre-invasive
lesions, such as ductal carcinoma in situ (DCIS), which has increased in incidence in the last
two decades due to increased screening.[1, 2] DCIS lesions harbor molecular changes that
characterize invasive breast cancers; yet not all DCIS progress into invasive disease.[3–5]
Anderson et al. (2004) performed a detailed analysis of incident DCIS and invasive breast can-
cer to assess the hypothesis that all invasive cancers have an in situ phase. They concluded that
incidence patterns observed in SEER (1973–2000) contradict the idea that carcinoma in situ
(CIS) is an obligate step in progression.[2] Others have argued that CIS is not an obligate pre-
cursor of invasive breast cancer due to a low probability of developing invasive breast cancer
after CIS diagnosis[6], variable rates of diagnoses of invasive breast cancer after DCIS ranging
from 14–53%[7–10], and autopsy studies reporting that 6–18% of the population may have
undetected DCIS at the time of death.[11, 12] Together these findings suggest that DCIS and
invasive breast cancer may represent distinct disease pathways, leading some to argue for a
narrower definition of breast cancer (to exclude DCIS).[13] It is clear that more research is
needed to distinguish indolent DCIS from lesions that will progress into invasive breast
cancers.
The aim of this study was to compare risk factor profiles for screen-detected DCIS and
invasive breast cancer among Luminal A lesions to try and elucidate the pathways that may be
important in etiology and progression of DCIS. Using the Carolina Breast Cancer Study, we
restricted analyses to Luminal A cases, which comprise a majority of DCIS cases[14], because
breast cancer represents multiple diseases (i.e. Luminal A, Luminal B, Basal-like, HER2-e-
nriched) with distinct risk factors[15–17] and the frequency of each subtype varies between
DCIS and invasive breast cancers due to length bias.[18–21] Second, the vast majority of DCIS
are detected by mammography, while invasive breast cancers are more often symptomatic.
Therefore, we further restricted analyses to screen-detected, Luminal A lesions in an effort to
isolate the influence of mode of detection and tumor heterogeneity. By controlling these vari-
ables, analyses comparing risk factors for DCIS and invasive disease can shed light on the role
of various exposures in breast cancer progression.
Methods
Study population
The Carolina Breast Cancer Study (CBCS) is a population-based study of African American
and Non-African American (98% Caucasian, referred to as White) women from 24 counties of
central and eastern North Carolina.[15, 22] The current analysis includes women from Phase
1 (1993–1996) and Phase 2 (1996–2001). Cases of invasive breast cancer were enrolled in
Phases 1 and 2. Women with carcinoma in situ (CIS) (both Lobular and Ductal Carcinoma In
Situ) were enrolled in Phase 2. African American and younger women (age <50) with invasive
breast cancer were oversampled using randomized recruitment[19], but there was no oversam-
pling by race or age for CIS cases. All participants provided informed consent as approved by
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer
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the Institutional Review Board at the University of North Carolina, School of Medicine, which
also provided approval for this study.
Cases were identified using rapid case ascertainment in collaboration with the North Caro-
lina Central Cancer Registry. Women between the ages of 20–74, diagnosed with primary
invasive breast cancer or DCIS, and who completed full questionnaires (described elsewhere
[15, 22]) were eligible. Controls were identified from North Carolina Division of Motor Vehi-
cles lists (age <65) and the Health Care Financing Administration (age�65) and were fre-
quency matched to cases by 5-year age and race. Separate control groups were selected for the
invasive breast cancer and CIS cases, taking into account the different sampling schema for the
two case groups. We restricted the main analysis to women eligible for routine screening
mammography (aged�40 years, as actual screening adherence for each control was
unknown), who had a screen-detected lesion (N = 203), and Luminal A tumors (defined as
HER2- and ER+ and/or PR+, N = 547). Invasive controls (N = 1,367) aged�40 years who
completed full questionnaires were included. A total of 503 CIS cases were enrolled in CBCS.
CIS inclusion criteria were similar to those for invasive breast cancer and resulted in the inclu-
sion of 108 cases in our main analyses: questionnaire completion, histological marker informa-
tion (explained elsehwere[15, 19]), aged�40 years, screen-detected lesions and Luminal A
(defined as HER2- and ER+, N = 139, representing 62% of all DCIS cases with information on
histological markers). A total of 424 CIS controls (aged�40 years) completed the full
questionnaire.
Immunohistochemistry
Cases granted permission to obtain medical records, pathology reports, and tumor blocks.[15]
Briefly, for invasive breast cancer, estrogen receptor (ER) and progesterone receptor (PR) sta-
tus was obtained from the medical records in 80% of cases (positive, negative; percent positiv-
ity was not available); for the remaining cases immunohistochemistry (IHC) was done at the
UNC Immunohistochemistry Core Laboratory. For DCIS cases, ER status was determined
using IHC. PR status was not available for DCIS cases. For all DCIS and invasive breast cancers
with available tissue sections, IHC was conducted for human epidermal growth factor receptor
2 (HER2) at UNC. Subtype definitions used for this study follow previously published studies.
[15, 19, 23]
Variables of interest. Body mass index (BMI) and waist-to-hip ratio (WHR) were mea-
sured by a trained nurse at the time of interview (approximately 0–6 months after diagnosis),
and the additional reproductive and lifestyle risk factors were self-reported through a nurse-
administered, questionnaire (approximately 0–6 months after diagnosis). ‘Mode of detection’
for the cases was defined from questionnaires and categorized as self-detected, medically-
detected, and screen-detected. Screen-detected women self-reported detection of their lesion
through a routine screening mammogram. Screening mammography was reported as the
mode of detection for 78% of Luminal A DCIS cases (n = 108) and 41% of Luminal A invasive
breast cancers cases (n = 203).
Statistical analysis. Logistic regression was used to estimate odds ratios (ORs) and 95%
confidence intervals (95% CIs) as the measure of association between risk factors and screen-
detected Luminal A DCIS or invasive breast cancer, comparing each case group with the
respective control group. The associations between the following risk factors and DCIS and
invasive disease were estimated: age at menarche (�13, >13), family history of breast cancer
(yes, no), alcohol use (ever, never), smoking status (ever, never), any physical activity in the
past three months (yes, no), BMI (continuous and<25, 25-<30,�30), WHR (<0.77, 0.77–
0.83,�0.84), number of full term pregnancies (nulliparious,1–2,�3), age at first full term
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pregnancy (years) (nulliparous, <26,�26), breastfeeding (ever, never), and duration of OC
use (years) (never,�3 months-�5, >5-�10, >10). All models were adjusted for the CBCS off-
set term to account for the sampling design of the study. We conducted tests of trend for BMI,
WHR, number of full-term pregnancies, and duration of OC use using the ordinal variable
and reporting the beta p-value. We estimated a p-interaction between DCIS and invasive
breast cancer to determine whether there was evidence of statistical heterogeneity in the effect
estimates between the two lesions for each risk factor.
Given that PR status was unavailable for DCIS cases, we performed sensitivity analyses
removing Luminal A invasive cases that were ER- but PR+ (n = 76, 12%); ORs were not sub-
stantially altered when this subgroup was excluded (results not shown). Additional sensitivity
analyses for risk factor associations including all Luminal A invasive breast cancers and DCIS
lesions regardless of age or mode of detection are provided in S1 Table. All statistical analyses
were done using SAS version 9.4 (SAS Institute, Cary NC). P-values were produced for a two-
sided test with an alpha of 0.05 for statistical significance.
Results
In the Carolina Breast Cancer Study, among women eligible for screening mammography
(�40 years of age), the prevalence of the Luminal A subtype was 62.3% among DCIS cases and
62.7% among invasive breast cancer cases. The majority of Luminal A DCIS were detected by
mammography (77.7%); a smaller proportion of Luminal A invasive breast cancers were
detected by mammography (41.1%). Compared to Luminal A invasive disease, a higher pro-
portion of Luminal A DCIS cases were African American (DCIS: 25.9% vs Invasive: 16.8%)
and were diagnosed among women with lower incomes (Table 1). The proportion of cases rep-
resented by postmenopausal women also differed between DCIS and invasive (DCIS: 75.9% vs
Invasive: 83.7%, respectively).
Case-control odds ratios (OR) and 95% confidence intervals (95% CI) for established breast
cancer risk factors in association with screen-detected Luminal A DCIS and invasive breast
cancer cases are presented in Table 2. Risk factor associations were not statistically different
between DCIS and invasive disease; however, there were some similarities and differences in
the patterns of association by tumor type. Similar patterns of association between tumor types
were seen for family history of breast cancer [DCIS OR: 1.59, 95% CI (0.97, 2.89); Invasive OR:
2.03, 95% CI (1.39, 2.97)], increasing parity [�3 vs 0 DCIS OR: 0.44, 95% CI (0.20, 0.97); Inva-
sive OR: 0.55, 95% CI (0.33, 0.92)], and first full term pregnancy before age 26 [DCIS OR: 0.44,
95% CI (0.20, 0.98); Invasive OR: 0.55, 95% CI (0.33, 0.92)].
Differences in direction of association were present for a number of risk factors. Ever breast-
feeding was not associated with DCIS [OR: 1.02, 95% CI (0.62–1.67)], but was weakly inversely
associated with invasive breast cancer [OR: 0.71, 95% CI (0.50, 1.02)]. Higher WHR (�0.84 ver-
sus<0.77) displayed an inverse association with DCIS [OR: 0.82, 95% CI (0.42, 1.60)], but was
positively associated with invasive breast cancer [OR: 1.99, 95% CI (1.25, 3.18)]. Likewise, being
obese (BMI�30 vs<25) was inversely associated with DCIS [OR: 0.77, 95% CI (0.44, 1.31)] and
positively associated with invasive breast cancer [OR: 1.30, 95% CI (0.87, 1.95)]. Oral contracep-
tive (OC) use for more than 10 years was differentially associated with DCIS and invasive breast
cancer, with a weakly protective association for DCIS and strongly associated with invasive dis-
ease [DCIS OR: 0.70, 95% CI (0.39, 1.74); Invasive OR: 1.80, 95% CI (1.02, 3.17)]. Physical activ-
ity was inversely associated with invasive disease and was not associated with DCIS.
Smoking and alcohol drinking showed stronger associations with DCIS than invasive dis-
ease. Ever drinking alcohol was positively associated with DCIS [OR: 1.63 95% CI (0.96–
2.79)], but the association was attenuated for invasive breast cancer [OR: 1.17 95% CI (0.81,
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0211488 January 25, 2019 4 / 11
1.68)]. Ever smoking was inversely associated with DCIS but not invasive disease [DCIS OR:
0.67 95% CI (0.41, 1.09); Invasive OR: 1.12 95% CI (0.80, 1.56)].
Additional analyses, including all cases of Luminal A DCIS and Luminal A invasive breast
cancer, regardless of age at diagnosis or mode of detection, are presented in S1 Table. To evalu-
ate the role of screen-detection in these association, we stratified findings on mode of detec-
tion. Overall, risk factor associations for Luminal A DCIS were similar in both magnitude and
direction to those observed among screen-detected lesions; effect estimates for Luminal A
invasive breast cancers were generally similar in magnitude and direction, but slightly attenu-
ated in medically-detected cases compared to those for screen-detected lesions.
Discussion
Using data from the population-based Carolina Breast Cancer Study Phases 1–2, we found
limited evidence that risk factor profiles may differ for screen-detected Luminal A DCIS
Table 1. Socio-demographic characteristics of screen detected Luminal A DCIS and invasive breast cancer in the Carolina Breast Cancer Study, Phases 1–2 (1993–
2001).
DCIS θ Invasive Breast Cancer�
Controls N (%^) Cases N (%^) Controls N (%^) Cases N (%^)
424 (100.0) 108 (77.7) 1367 203 (41.1)
Age at diagnosis/ selection (yrs.)
40–49 124 (41.8) 26 (24.1) 590 (44.6) 58 (16.4)
50–59 151 (33.4) 30 (27.8) 336 (29.8) 62 (35.3)
60–69 103 (18.1) 38 (35.2) 290 (17.2) 60 (35.7)
�70 46 (6.7) 14 (13.0) 151 (8.5) 23 (12.6)
Menopausal status
Pre 121 (40.7) 26 (24.1) 528 (41.1) 53 (16.3)
Post 303 (59.3) 82 (75.9) 839 (58.9) 150 (83.7)
Race
White 356 (82.1) 83 (76.9) 751 (79.4) 124 (84.9)
African American 68 (17.9) 25 (23.1) 616 (20.6) 79 (15.1)
First degree family history of BC
No 362 (87.1) 84 (80.0) 1150 (87.2) 152 (78.4)
Yes 56 (12.9) 21 (20.0) 167 (12.8) 46 (21.6)
Missing 6 3 50 5
Highest level of education
Less than High School 61 (13.0) 8 (7.5) 280 (14.2) 36 (11.3)
High School Post High School 240 (56.6) 69 (63.9) 749 (56.5) 113 (59.9)
Collage or more 123 (30.5) 31 (28.7) 337 (29.2) 54 (28.8)
Missing 0 0 1 0
Income per year
<$15,000 45 (9.7) 21 (20.8) 288 (15.4) 41 (13.1)
$15,000-$30,000 103 (25.3) 25 (24.8) 270 (19.9) 36 (17.8)
$30,000-$50,000 92 (24.5) 21 (20.8) 296 (24.9) 49 (32.7)
�$50,000 146 (40.5) 34 (33.7) 388 (39.8) 64 (36.3)
Missing 38 7 125 13
θ DCIS Luminal A lesions were defined as: HER2- and ER+ lesions.
�Invasive Luminal A lesions were defined as: HER2- (ER+ or PR+) stratified by mode of detection.
^All percentages weighted for sampling design
https://doi.org/10.1371/journal.pone.0211488.t001
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Table 2. Odds Ratios (OR) and 95% Confidence Intervals (95% CI) for screen detected Luminal A DCIS and inva-
sive breast cancer cases (among women�40 years of age) compared to the respective controls from the Carolina
Breast Cancer Study, Phases1-2 (1993–2001).
Luminal A DCISθ Luminal A Invasive� Invasive vs
DCIS
Controls
N (%^)
Cases N
(%^)
OR (95% CI) Controls N
(%^)
Cases N
(%^)
OR (95% CI) p-interactiond
Number of full-term pregnanciesa
Nulliparous 48
(13.6)
16 (14.8) Ref 132 (10.0) 36 (16.9) Ref 0.4
1–2 214
(51.6)
57 (52.8) 0.75 (0.37–
1.53)
661 (52.8) 88 (44.0) 0.56 (0.35–
0.89)
�3 162
(34.7)
35 (32.4) 0.44 (0.20–
0.97)
574 (37.2) 79 (39.1) 0.55 (0.33–
0.92)
p-trend 0.02 0.07
Age at first full term pregnancy
(years)a
Nulliparous 48
(13.6)
16 (14.8) Ref 132 (10.0) 36 (16.9) Ref
<26 283
(64.4)
67 (62.0) 0.44 (0.20–
0.98)
959 (66.5) 131 (63.7) 0.55 (0.33–
0.92)
�26 93
(22.0)
25 (23.1) 0.44 (0.17–
1.13)
273 (23.5) 36 (19.4) 0.59 (0.31–
1.14)
Missing 0 0 3 0
Family history of
breast cancera
No 362
(87.1)
84 (80.0) Ref 1150 (87.2) 152 (78.4) Ref 0.5
Yes 56 (12.9) 21 (20.0) 1.59 (0.87–
2.89)
167 (167) 46 (21.6) 2.03 (0.39–
2.97)
Missing 6 3 1 5
Alcohol usea
Never 156
(34.6)
34 (31.5) Ref 459 (30.1) 63 (28.7) Ref 0.5
Ever 267
(65.4)
74 (68.5) 1.63 (0.96–
2.79)
907 (69.9) 140 (71.3) 1.17 (0.81–
1.68)
Missing 1 0 0 0
BMIb
<25 142
(34.7)
45 (41.7) Ref 426 (38.4) 61 (36.5) Ref 0.08
25-<30 133
(30.2)
24 (22.2) 0.56 (0.31–
1.00)
418 (30.1) 60 (33.9) 1.10 (0.74–
1.65)
�30 149
(35.2)
39 (36.1) 0.76 (0.44–
1.31)
523 (31.5) 82 (29.6) 1.30 (0.87–
1.95)
p-trend 0.30 0.19
WHRa
<0.77 129
(32.7)
29 (26.9) Ref 416 (36.9) 40 (23.5) Ref 0.1
0.77–0.83 148
(34.3)
41 (38.0) 0.98 (0.54–
1.77)
427 (31.7) 73 (40.5) 1.95 (0.26–
3.04)
�0.84 147
(33.1)
38 (35.2) 0.82 (0.42–
1.60)
524 (31.4) 90 (36.0) 1.99 (1.25–
3.18)
p-trend 0.54 <0.01
Duration of oral contraceptive use
(years)a
(Continued)
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer
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compared to screen-detected Luminal A invasive breast cancer. Although no statistically sig-
nificant interactions were detected, differences in the direction of association were observed
for measures of adiposity (BMI and WHR) and oral contraceptive use for DCIS and invasive
Table 2. (Continued)
Luminal A DCISθ Luminal A Invasive� Invasive vs
DCIS
Controls
N (%^)
Cases N
(%^)
OR (95% CI) Controls N
(%^)
Cases N
(%^)
OR (95% CI) p-interactiond
never 154
(29.5)
46 (43.9) Ref 540 (32.6) 88 (45.9) Ref 0.07
�3 months-
�5
149
(38.3)
41 (38.3) 1.21 (0.67–
2.18)
501 (40.1) 57 (27.2) 0.98 (0.64-
.148)
>5-�10 71 (19.9) 12 (11.2) 0.66 (0.29–
1.53)
195 (16.4) 34 (15.5) 1.57 (0.95–
2.61)
>10 48 (12.3) 8 (7.5) 0.70 (0.39–
1.74)
120 (10.8) 24 (11.5) 1.80 (1.02–
3.17)
Missing 2 1 11 0
p-trend 0.27 0.02
Smoking statusa
Never 231
(55.7)
65 (60.2) Ref 730 (51.2) 99 (41.8) Ref 0.1
Ever 193
(44.3)
43 (39.8) 0.67 (0.41–
1.09)
637 (48.8) 104 (58.2) 1.12 (0.80–
1.56)
Age at menarchea
�13 335
(80.0)
83 (76.6) Ref 998 (75.1) 155 (75.1) Ref 0.5
>13 89 (20.0) 25 (23.1) 1.12 (0.66–
1.92)
362 (24.9) 48 (24.9) 0.89 (0.61–
1.27)
Missing 0 0 7 0
Ever lactatedc
No 210
(56.1)
48 (52.2) Ref 700 (57.3) 100 (58.3) Ref 0.1
Yes 166
(43.9)
44 (47.3) 1.02 (0.62–
1.67)
535 (42.7) 67 (41.7) 0.71 (0.50–
1.02)
Physical activitya
No 182
(45.4)
46 (42.6) Ref 651 (45.2) 104 (47.4) Ref 0.5
Yes 241
(54.6)
62 (57.4) 1.01 (0.63–
1.62)
714 (54.8) 99 (52.6) 0.79 (0.58–
1.09)
θDCIS Luminal A lesions were defined as: HER2- and ER+ lesions.
�Invasive Luminal A lesions were defined as: HER2- (ER+ or PR+).
^All percentages weighted for study sampling design
aFull model included: offset term, age (continuous) and race (African American, non-African American), family
history (yes, no), alcohol use (ever, never), smoking (ever, never), oral contraceptive use (ever, never), number of full
term pregnancy (0,1–2,�3), breastfeeding (ever, never), age at menarche (�13, >13 years), BMI (continuous),
postmenopausal status (pre, post)
bFull model included: offset term, age, race, family history, alcohol use, smoking, oral contraceptive use, number of
full term pregnancy, breastfeeding, age at menarche, postmenopausal status
cFull model (among parous women only) included: offset term, age, race, family history, alcohol use, smoking, oral
contraceptive use, breastfeeding, age at menarche, postmenopausal status
dInteraction models adjusted for: offset term, age, and race
https://doi.org/10.1371/journal.pone.0211488.t002
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disease. Ever smoking was inversely associated with DCIS, but not invasive disease. We also
observed that ever breastfeeding and physical activity were inversely associated with risk of
invasive disease, but not DCIS. Risk factor profiles were similar between the two groups for
family history of breast cancer, number of full-term pregnancies, and age at first full term
pregnancy.
Many of the associations we observed track with published literature reports. As reported
previously in the literature by Kabat et al. (2010) and Trentham-Dietz et al. (2007), we
observed an inverse relationship between ever smoking and risk of Luminal A DCIS.[24, 25]
This relationship may be causal in nature or may be a result of lower smoking levels among
women who attended mammography screening. For invasive disease, we observed a slightly
elevated, though non-significant, association similar in magnitude to that reported by Young
et al. (2009) and Furberg et al. (2002)[26, 27] and by previous papers in the CBCS1/2[28] and
the AMBER consortium.[29] Adiposity measures showed complex relationships with risk. The
literature on BMI and risk of DCIS are consistent with our results in that high BMI has been
associated with decreased DCIS risk[30–32] and increased risk of invasive disease, particularly
among postmenopausal women.[33, 34] We saw a similar pattern for WHR. Previous litera-
ture suggests a positive association between WHR and invasive disease, but a null association
for DCIS.[35] Differential patterns of association for OC use and breastfeeding were also sup-
ported by previous literature.[15, 23, 30, 36–43] An advantage of the current analysis is that
the comparison between DCIS and invasive disease were conducted within a single popula-
tion-based, well-defined and racially diverse study.
A previous CBCS analysis investigated differences between DCIS and invasive breast cancer
wherein all DCIS were stratified by pathological subtype (comedo vs. non-comedo) and found
comedo DCIS to have similar risk factor profiles to invasive breast cancer, whereas non-com-
edo DCIS may represent a distinct etiology.[23] In more recent years, a molecular subtyping of
breast cancer has become more predominant for describing clinical heterogeneity. Most Lumi-
nal A breast cancers are non-comedo, and therefore, the suggestion of distinct etiology from
the previous study parallels what we find here for molecular subtype. Screen-detected Luminal
A invasive breast cancer is the ideal comparison group for Luminal A DCIS lesions because
mammography is associated with other potential confounders (obesity, breastfeeding, etc.)
[44–46], and the majority of DCIS diagnoses are screen-detected.
Our study has some limitations. First, we had limited sample size to investigate the interac-
tions between DCIS and invasive disease and most of our interaction tests were not statistically
significant. Second, we used IHC markers to act as a surrogate for Luminal A subtype.
Although progesterone receptor (PR) was assessed for invasive and not DCIS cases, it was
uncommon for invasive breast cancer in the CBCS to be PR positive and ER negative and
therefore differentiation between subgroups of hormone receptor positive cancers was not
possible. However, sensitivity analyses showed that exclusion of invasive breast cancers that
were only PR positive did not substantially alter associations. Third, we acknowledge potential
misclassification of the self-reported mode of detection, because this data was not confirmed
by medical records or mammography history. Additionally, we do not expect any recall bias
for lifestyle factors to differentially influence DCIS or invasive cases. We do not expect differ-
ential misclassification of mode of detection by DCIS or invasive breast cancer. By restricting
our analysis to screen-detected invasive breast cancer and screening-eligible controls we have
focused on a smaller subset of tumors, and our findings may not generalizable to other sub-
types (i.e. Basal-like) and ages (e.g. breast cancer before age 40 years). However, our analysis
has maximized internal validity to compare DCIS and invasive disease. Finally, analyses such
as ours are helpful in identifying etiologic differences between diseases but are not well-suited
to identify biologic mechanisms.
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0211488 January 25, 2019 8 / 11
The widespread use of mammography has increased detection of both DCIS lesions and
invasive breast cancers over the past decades.[1, 2] Identifying risk factors shared by DCIS and
invasive breast cancer that may be associated with a higher likelihood of progression to inva-
sive disease remains an important challenge for reducing the breast cancer burden. While it is
difficult to determine the induction periods for breast cancer risk factor associations, perform-
ing studies on precursor lesions may help to elucidate risk factors associated with progression.
The current analysis suggests that progression from DCIS to invasive disease may be associated
with oral contraceptives and adiposity.
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